Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
May 06, 2023
First Horizon shares dropped after the $13.4 billion merger with TD Bank was called off on Thursday.

First Horizon shares dropped after the $13.4 billion merger with TD Bank was called off on Thursday.

"The companies mutually terminated the deal, which was originally announced in late February 2022, due to uncertainty around TD's ability to obtain regulatory approval and when.

On this news, shares of First Horizon fell by more than 36%. TD's shares, listed on the New York Stock Exchange, remained unchanged.

Brian Jordan, CEO of First Horizon, said, "While today's announcement is disappointing and unexpected, First Horizon will continue its growth trajectory, operating from a position of strength and stability."

"Our strong capital position, disciplined credit quality, expense control measures, and well-diversified and stable funding base have enabled our business to navigate the challenging dynamics of the banking industry and remain focused on executing our customer-focused growth plan," he continued."

"On April 25, 2023, the Momentum Indicator of FHN moved below the 0 level, indicating a potential sell signal. In such cases, traders may want to consider selling the stock, shorting the stock, or exploring put options on FHN as a result. Based on historical data, in 48 out of 84 instances where the Momentum Indicator fell below 0, the stock fell further within the subsequent month, resulting in a 57% chance of a continued downward trend.

Moreover, the Moving Average Convergence Divergence Histogram (MACD) for FHN turned negative on May 02, 2023, which could be an indication of a further decline in the stock's price in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor analyzed 43 similar instances when the MACD indicator turned negative, and found that in 24 of those cases, the stock turned lower in the days that followed, resulting in a 56% chance of success."

Related Ticker: FHN

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


FHN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 22, 2026

FHN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 38 cases where FHN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FHN's RSI Indicator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 34 of 50 cases where FHN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.

The Moving Average Convergence Divergence (MACD) for FHN just turned positive on October 05, 2026. Looking at past instances where FHN's MACD turned positive, the stock continued to rise in 28 of 48 cases over the following month. The odds of a continued upward trend are 58%.

Following a +1.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHN advanced for three days, in 180 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FHN as a result. In 41 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 51%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

The Aroon Indicator for FHN entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 9 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.295) is normal, around the industry mean (1.321). P/E Ratio (11.149) is within average values for comparable stocks, (24.015). Projected Growth (PEG Ratio) (0.050) is also within normal values, averaging (1.186). Dividend Yield (0.029) settles around the average of (0.030) among similar stocks. P/S Ratio (3.448) is also within normal values, averaging (3.747).

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. FHN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 56 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 57, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

Notable companies

The most notable companies in this group are Itau Unibanco Banco Holding SA (NYSE:ITUB), US Bancorp (NYSE:USB), PNC Financial Services Group (NYSE:PNC), Deutsche Bank Aktiengesellschaft (NYSE:DB), Banco Bradesco SA (NYSE:BBD), Huntington Bancshares (NASDAQ:HBAN), Regions Financial Corp (NYSE:RF), KeyCorp (NYSE:KEY).

Industry description

Regional banks have a smaller reach than major banks, and cater mostly to one region of a country, such as a state or within a group of states. They offer services often similar – albeit with some limitations/smaller scale – compared to major banks. Taking deposits, making loans, mortgages, leases, credit cards , fund management, insurance and investment banking. SunTrust Banks, State Street Corp., M&T Bank Corp. are some examples of U.S. regional banks.

Market Cap

The average market capitalization across the Regional Banks Industry is 6.12B. The market cap for tickers in the group ranges from 22.65 to 173.74B. DBSDF holds the highest valuation in this group at 173.74B. The lowest valued company is VLYPP at 22.65.

High and low price notable news

The average weekly price growth across all stocks in the Regional Banks Industry was 1%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 7%. INTR experienced the highest price growth at 30%, while SHFS experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Regional Banks Industry was 61%. For the same stocks of the Industry, the average monthly volume growth was 173% and the average quarterly volume growth was 48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 50
Price Growth Rating: 49
SMR Rating: 38
Profit Risk Rating: 57
Seasonality Score: 53 (-100 ... +100)
View a ticker or compare two or three
FHN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a regional bank

Industry RegionalBanks

Industry
Regional Banks
Address
165 Madison Avenue
Phone
+1 901 523-4444
Employees
7404
Web
https://www.firsthorizon.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.
MU shares are declining approximately -6.00% in premarket trading on April 2, 2026, pulling back to roughly $353.70 from the prior session's close of $376.27. The primary catalyst is a sweeping new round of tariff announcements from the Trump administration, dubbed by markets as "Liberation Day 2.0," which has sparked a broad risk-off selloff across technology and semiconductor stocks
Shares of Robinhood Markets are down approximately 6.15% in Thursday's intraday session, trading around $65.80 after closing at $70.11 on April 1, 2026. Wolfe Research delivered a sharp blow by cutting its price target on HOOD by 30%, citing persistent weakness in crypto trading volumes as a core drag on revenue.